Frontiers in Oncology : Impact Factor & More
eISSN: 2234-943XpISSN: 2234-943X
Open AccessShare this on:
Key Metrics
CiteScore 
4.5
Eigenfactor
0.01 - 0.05
Impact Factor
< 5
Scite Index
0.89 5-Year SI
SJR
Q3Oncology
SNIP
1.19
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Frontiers in Oncology
Frontiers in Oncology Journal Specifications
Indexed in the following public directories
Web of Science 
DOAJ 
SJR
| Overview | |
| Publisher | FRONTIERS MEDIA SA |
| Language | English |
| Frequency | Continuous publication |
| Article Processing Charges | USD 2950 |
| Publication Time | 14 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Frequency | Continuous publication |
| Publication Start Year | 2011 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY |
| OA statement | Visit website |
View less
Planning to publish in Frontiers in Oncology ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Frontiers in Oncology
Expanding the spectrum of non-canonical NUT carcinoma: clinicopathological and molecular characterization of BRD3::NUTM1 and WWTR1::NUTM1 fusion variants
- 1 Jul 2026
- Frontiers in Oncology
CTSG-expressing mast cells confer resistance to immunotherapy in colorectal cancer
- 1 Jul 2026
- Frontiers in Oncology
Established and emerging prognostic factors in mycosis fungoides and Sézary syndrome
- 1 Jul 2026
- Frontiers in Oncology
Long term survival of patients with alpha-fetoprotein-positive hepatoid adenocarcinoma of the gallbladder: a case report and literature review
- 30 Jun 2026
- Frontiers in Oncology
Establishment, functional dissection, and single-cell transcriptomal characteristics of patient-derived pulmonary sarcomatoid carcinoma organoids
- 29 Jun 2026
- Frontiers in Oncology
Aerobic exercise training attenuates the deleterious effects of walker-256 cancer: effects on physical capacity, cachexia, and cardiac mass
- 29 Jun 2026
- Frontiers in Oncology
Expanding the spectrum of non-canonical NUT carcinoma: clinicopathological and molecular characterization of BRD3::NUTM1 and WWTR1::NUTM1 fusion variants
- 1 Jul 2026
- Frontiers in Oncology
CTSG-expressing mast cells confer resistance to immunotherapy in colorectal cancer
- 1 Jul 2026
- Frontiers in Oncology
Established and emerging prognostic factors in mycosis fungoides and Sézary syndrome
- 1 Jul 2026
- Frontiers in Oncology
Long term survival of patients with alpha-fetoprotein-positive hepatoid adenocarcinoma of the gallbladder: a case report and literature review
- 30 Jun 2026
- Frontiers in Oncology
Establishment, functional dissection, and single-cell transcriptomal characteristics of patient-derived pulmonary sarcomatoid carcinoma organoids
- 29 Jun 2026
- Frontiers in Oncology
Aerobic exercise training attenuates the deleterious effects of walker-256 cancer: effects on physical capacity, cachexia, and cardiac mass
- 29 Jun 2026
- Frontiers in Oncology
FAQs on Frontiers in Oncology
How long has Frontiers in Oncology been actively publishing? 
What is the publishing frequency of Frontiers in Oncology?
How many articles did Frontiers in Oncology publish last year?
What is the eISSN & pISSN for Frontiers in Oncology?
What is Citescore for Frontiers in Oncology?
What is SNIP score for Frontiers in Oncology?
What is the SJR for Frontiers in Oncology?
Who is the publisher of Frontiers in Oncology?
